WO1997011718A1 - Inhibitors of integrin receptors and their therapeutical uses - Google Patents
Inhibitors of integrin receptors and their therapeutical uses Download PDFInfo
- Publication number
- WO1997011718A1 WO1997011718A1 PCT/GB1996/002366 GB9602366W WO9711718A1 WO 1997011718 A1 WO1997011718 A1 WO 1997011718A1 GB 9602366 W GB9602366 W GB 9602366W WO 9711718 A1 WO9711718 A1 WO 9711718A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitor
- activation
- integrin receptor
- healing
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU70901/96A AU7090196A (en) | 1995-09-27 | 1996-09-25 | Inhibitors of integrin receptors and their therapeutical uses |
JP9513215A JPH11511478A (en) | 1995-09-27 | 1996-09-25 | Integrin receptor inhibitors and their therapeutic use |
EP96931895A EP0852504A1 (en) | 1995-09-27 | 1996-09-25 | Inhibitors of integrin receptors and their therapeutical uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9519667.1A GB9519667D0 (en) | 1995-09-27 | 1995-09-27 | Pharmaceutical composition |
GB9519667.1 | 1995-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997011718A1 true WO1997011718A1 (en) | 1997-04-03 |
Family
ID=10781329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/002366 WO1997011718A1 (en) | 1995-09-27 | 1996-09-25 | Inhibitors of integrin receptors and their therapeutical uses |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0852504A1 (en) |
JP (1) | JPH11511478A (en) |
AU (1) | AU7090196A (en) |
CA (1) | CA2233138A1 (en) |
GB (1) | GB9519667D0 (en) |
WO (1) | WO1997011718A1 (en) |
ZA (1) | ZA968081B (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999061040A2 (en) * | 1998-05-22 | 1999-12-02 | Boys Town National Research Hospital | USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE |
WO2000064474A1 (en) * | 1999-04-22 | 2000-11-02 | Biogen, Inc. | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
US6486174B2 (en) | 2000-08-07 | 2002-11-26 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
US6492325B1 (en) | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
EP2075258A1 (en) * | 2006-10-26 | 2009-07-01 | Gene Techno Science Co., Ltd. | Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same |
US8084031B2 (en) | 1999-06-01 | 2011-12-27 | Biogen Idec Ma Inc. | Method for the treatment of inflammatory disorders |
US8084028B2 (en) | 2001-04-13 | 2011-12-27 | Biogen Idec Ma Inc. | Antibodies to VLA-1 |
US8563690B2 (en) | 2008-11-03 | 2013-10-22 | The Board Of Trustees Of The University Of Illinois | Modulation of platelet aggregation |
US8614296B2 (en) | 2008-04-24 | 2013-12-24 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof |
US8617829B2 (en) | 2009-09-24 | 2013-12-31 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof |
US20140134192A1 (en) * | 2010-12-21 | 2014-05-15 | Leidos, Inc. | Methods and Compositions For Wound Treatment |
WO2015039020A1 (en) * | 2013-09-15 | 2015-03-19 | The Johns Hopkins University | Integrin-modulating therapies for treating fibrotic disease |
US10119979B2 (en) | 2006-05-25 | 2018-11-06 | Biogen Ma Inc. | Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies |
US10160808B2 (en) | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0220957A2 (en) * | 1985-10-28 | 1987-05-06 | Scripps Clinic And Research Foundation | Platelet binding inhibitors |
WO1989011538A1 (en) * | 1988-05-18 | 1989-11-30 | Centocor, Inc. | Platelet-specific chimeric immunoglobulin |
EP0368486A2 (en) * | 1988-11-10 | 1990-05-16 | Merck & Co. Inc. | Novel inhibitors of platelet binding |
WO1992008982A1 (en) * | 1990-11-15 | 1992-05-29 | The Scripps Research Institute | Characterization of platelet aggregation disorders |
WO1992008739A1 (en) * | 1990-11-13 | 1992-05-29 | The Scripps Research Institute | Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation |
WO1993000108A1 (en) * | 1991-06-28 | 1993-01-07 | Corvas International, Inc. | Novel inhibitors of platelet aggregation |
JPH05111390A (en) * | 1991-10-21 | 1993-05-07 | Nippon Shinyaku Co Ltd | Monoclonal antibody and productive cell therefor |
WO1993019783A1 (en) * | 1992-04-01 | 1993-10-14 | The Whittier Institute For Diabetes And Endocrinology | Methods of inhibiting or enhancing scar formation in the cns |
-
1995
- 1995-09-27 GB GBGB9519667.1A patent/GB9519667D0/en active Pending
-
1996
- 1996-09-25 JP JP9513215A patent/JPH11511478A/en active Pending
- 1996-09-25 AU AU70901/96A patent/AU7090196A/en not_active Abandoned
- 1996-09-25 EP EP96931895A patent/EP0852504A1/en not_active Withdrawn
- 1996-09-25 WO PCT/GB1996/002366 patent/WO1997011718A1/en not_active Application Discontinuation
- 1996-09-25 CA CA002233138A patent/CA2233138A1/en not_active Abandoned
- 1996-09-26 ZA ZA9608081A patent/ZA968081B/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0220957A2 (en) * | 1985-10-28 | 1987-05-06 | Scripps Clinic And Research Foundation | Platelet binding inhibitors |
WO1989011538A1 (en) * | 1988-05-18 | 1989-11-30 | Centocor, Inc. | Platelet-specific chimeric immunoglobulin |
EP0368486A2 (en) * | 1988-11-10 | 1990-05-16 | Merck & Co. Inc. | Novel inhibitors of platelet binding |
WO1992008739A1 (en) * | 1990-11-13 | 1992-05-29 | The Scripps Research Institute | Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation |
WO1992008982A1 (en) * | 1990-11-15 | 1992-05-29 | The Scripps Research Institute | Characterization of platelet aggregation disorders |
WO1993000108A1 (en) * | 1991-06-28 | 1993-01-07 | Corvas International, Inc. | Novel inhibitors of platelet aggregation |
JPH05111390A (en) * | 1991-10-21 | 1993-05-07 | Nippon Shinyaku Co Ltd | Monoclonal antibody and productive cell therefor |
WO1993019783A1 (en) * | 1992-04-01 | 1993-10-14 | The Whittier Institute For Diabetes And Endocrinology | Methods of inhibiting or enhancing scar formation in the cns |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Week 9323, Derwent World Patents Index; AN 93-184811, XP002024815 * |
R. HERSHKOVITZ ET AL.: "Nonpeptidic analogogues of the Arg-Gly-Asp (RGD) sequence specifically inhibit the adhesion of human tenon's capsule fibroblasts to fibronectin.", INVESTIGATIVE OPHTALMOLOGY & VISUAL SCIENCE, vol. 35, no. 5, April 1994 (1994-04-01), ST. LOUIS, MO, USA, pages 2585 - 2591, XP000616130 * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999061040A2 (en) * | 1998-05-22 | 1999-12-02 | Boys Town National Research Hospital | USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE |
WO1999061040A3 (en) * | 1998-05-22 | 2000-01-27 | Boys Town National Research Ho | USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE |
JP2002516287A (en) * | 1998-05-22 | 2002-06-04 | ボーイズ タウン ナショナル リサーチ ホスピタル | Use of α1β1 integrin receptor inhibitor and IGF-β1 inhibitor in the treatment of kidney disease |
US6492325B1 (en) | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
AU761928B2 (en) * | 1998-05-22 | 2003-06-12 | Boys Town National Research Hospital | Use of alpha1beta1 integrin receptor inhibitors and TGF-beta1 inhibitors in the treatment of kidney disease |
SG117434A1 (en) * | 1998-05-22 | 2005-12-29 | Boys Town Nat Res Hospital | Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
WO2000064474A1 (en) * | 1999-04-22 | 2000-11-02 | Biogen, Inc. | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
CZ301636B6 (en) * | 1999-04-22 | 2010-05-12 | Biogen Idec Ma Inc. | Pharmaceutical composition for treating fibrosis containing composition comprising antibody homologue antagonizing interaction of integrin alpha-4 subunit with said integrin ligand |
US6652856B2 (en) | 1999-04-22 | 2003-11-25 | Biogen, Inc. | Method for the treatment of fibrosis |
AU783054B2 (en) * | 1999-04-22 | 2005-09-22 | Biogen Ma Inc. | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
CN1332714C (en) * | 1999-04-22 | 2007-08-22 | 比奥根艾迪克Ma公司 | Method for treating fibrosis by utilizing integrin alpha 4 subunit antagonist |
US9902774B2 (en) | 1999-06-01 | 2018-02-27 | Biogen Ma Inc. | Method for the treatment of inflammatory disorders |
US8557240B2 (en) | 1999-06-01 | 2013-10-15 | Biogen Idec Ma Inc. | Method for the treatment of inflammatory disorders |
US8084031B2 (en) | 1999-06-01 | 2011-12-27 | Biogen Idec Ma Inc. | Method for the treatment of inflammatory disorders |
US6486174B2 (en) | 2000-08-07 | 2002-11-26 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
US8084028B2 (en) | 2001-04-13 | 2011-12-27 | Biogen Idec Ma Inc. | Antibodies to VLA-1 |
US9644030B2 (en) | 2001-04-13 | 2017-05-09 | Biogen Ma Inc. | Antibodies to VLA-1 |
US10119979B2 (en) | 2006-05-25 | 2018-11-06 | Biogen Ma Inc. | Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies |
EP2075258A4 (en) * | 2006-10-26 | 2010-08-04 | Gene Techno Science Co Ltd | Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same |
US8901280B2 (en) | 2006-10-26 | 2014-12-02 | Gene Techno Science Co., Ltd. | Antibody against RGD in amino acid sequence of extracellular matrix protein and production method and use of the same |
EP2075258A1 (en) * | 2006-10-26 | 2009-07-01 | Gene Techno Science Co., Ltd. | Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same |
US8614296B2 (en) | 2008-04-24 | 2013-12-24 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof |
US8563690B2 (en) | 2008-11-03 | 2013-10-22 | The Board Of Trustees Of The University Of Illinois | Modulation of platelet aggregation |
US8617829B2 (en) | 2009-09-24 | 2013-12-31 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof |
US9387253B2 (en) | 2010-12-21 | 2016-07-12 | Leidos, Inc. | Methods and compositions for wound treatment |
US9238068B2 (en) * | 2010-12-21 | 2016-01-19 | Leidos, Inc. | Methods and compositions for wound treatment |
US10101339B2 (en) | 2010-12-21 | 2018-10-16 | Leidos, Inc. | Methods and compositions for wound treatment |
US20140134192A1 (en) * | 2010-12-21 | 2014-05-15 | Leidos, Inc. | Methods and Compositions For Wound Treatment |
US10160808B2 (en) | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
US10316095B2 (en) | 2012-02-16 | 2019-06-11 | Santarus, Inc. | Antibody formulations |
WO2015039020A1 (en) * | 2013-09-15 | 2015-03-19 | The Johns Hopkins University | Integrin-modulating therapies for treating fibrotic disease |
Also Published As
Publication number | Publication date |
---|---|
JPH11511478A (en) | 1999-10-05 |
AU7090196A (en) | 1997-04-17 |
EP0852504A1 (en) | 1998-07-15 |
ZA968081B (en) | 1998-03-26 |
GB9519667D0 (en) | 1995-11-29 |
CA2233138A1 (en) | 1997-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0646012B1 (en) | WOUND HEALING AND TREATMENT OF FIBROTIC DISORDERS BY TGFbeta-3 | |
WO1997011718A1 (en) | Inhibitors of integrin receptors and their therapeutical uses | |
EP0754058B1 (en) | Wound healing | |
JP3333507B2 (en) | Wound healing | |
JP4307561B2 (en) | Wound healing | |
WO2005074984A1 (en) | Hmgb1 protein inhibitors for the regulation of smooth muscle cells and endothelial cells profileration | |
JP2002542298A (en) | Pharmaceutical formulations containing low molecular weight thrombin inhibitors and their prodrugs | |
AU2013202269A1 (en) | Compositions and methods for the treatment of fibrosis and fibrotic diseases | |
US7220413B2 (en) | Pharmaceutical composition containing inhibitors of interferon-γ | |
US6140307A (en) | Pharmaceutical composition | |
JP3745624B2 (en) | Methods for limiting scarring and adhesion formation | |
EP0972521B1 (en) | Pharmaceutical composition containing stimulators of interferon-gamma | |
KR100699509B1 (en) | Treatment with small peptides to effect antifibrotic activity | |
EP0841937B1 (en) | Use of betaglycan to reduce scarring | |
DE60017793T2 (en) | METHOD FOR PREVENTING AND TREATING DAMAGE TO THE TISSUE TISSUE | |
US6900181B2 (en) | Pharmaceutical composition | |
US7727520B2 (en) | Method of promoting the healing of a chronic wound | |
WO1992021363A1 (en) | Inhibition of smooth muscle cell proliferation by vitronectin | |
AU2002301776B2 (en) | Pharmaceutical Composition | |
WO2006014518A2 (en) | Promotion of wound healing | |
JPH06157332A (en) | Medicinal composition for curing revasocontriction after revascularization and arteriosclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996931895 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2233138 Country of ref document: CA Ref country code: JP Ref document number: 1997 513215 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2233138 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996931895 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996931895 Country of ref document: EP |